Mecuris successfully closes a Series A financing round of €3.6 million. In addition to existing seed investors Bayern Kapital and High-Tech Gründerfonds, Vesalius Biocapital, Mulcan International Investments, and a hospital chain are now on board.
The Munich-based medical technology startup Mecuris specializes in the digitalization of prostheses and orthoses. With the help of a cloud-based platform, physicians and orthopedic technicians are empowered to create prostheses and orthoses—customized to each patient—using 3D printing.
Three new and two proven investors
The approach of using and monetizing digitalization for personalized orthoses and prostheses has convinced new and existing investors. The founding team was able to attract three new investors for Series A financing: Vesalius Biocapital III SICAR, MII Mulcan International Investments GmbH, and one of the five largest hospital chains in Germany and Europe. The latter aims to open up digitalization for its partners—medical supply stores.
In addition, the seed investors Bayern Kapital and High-Tech Gründerfonds will continue to support the company's goals.
Development of the European market
Mecuris will use the proceeds from the financing round to expand into the European market and strengthen its sales. Furthermore, the startup will continue to develop new digital solutions to complement its portfolio and close market gaps that other players cannot currently serve.
